By Mareia Frost (Abzena)2023-02-24T09:00:58
In this article, Mareia Frost, Scientific Leader at Abzena, explores how understanding the characteristics of protein‑based drugs, and applying the right techniques, means even the most complex biologics can be effectively separated from potentially-harmful impurities.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-10-22T14:00:00
Sponsored by Bruker
2025-09-24T15:24:00
Sponsored by Lonza
2026-02-09T10:00:00 2026-02-09T11:00:00
Sponsored by Emerson
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, By European Pharmaceutical Review
2025-09-19T15:55:00
Sponsored by Sartorius, By Marko Narobe (Sartorius Biosepartions), Michael Gerrero (BridgeBio) and Srivatsan Ramesh (BridgeBio)
Site powered by Webvision Cloud